公开(公告)号：WO2015130840A2

公开(公告)日：2015-09-03

申请号：PCT/US2015/017595

申请日：2015-02-25

Applicant: CODA THERAPEUTICS, INC.

Inventor： PHILLIPS, Anthony ,  BANNAN, Scott ,  MATSUOKA, Grove ,  DUFT, Bradford

IPC: A01H5/00 ,  C12N15/82

CPC classification number: C12N15/113 ,  C12N2310/11

Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.

公开(公告)号：WO2014145342A2

公开(公告)日：2014-09-18

申请号：PCT/US2014/030082

申请日：2014-03-15

Applicant: CODA THERAPEUTICS, INC.

Inventor： PHILLIPS, Anthony ,  EISENBUD, David ,  BANNAN, Scott ,  POOL, David ,  MATSUOKA, Grove ,  SUNDERLAND, Tracey ,  DUFT, Bradford

IPC: H04S5/00

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白试剂，特别是抗连接蛋白43反义多核苷酸来治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于令人惊讶且意外的发现，即在预处理阶段期间不增加或减小超过预定量的慢性伤口更适于成功治疗 伤口的大小在预处理阶段期间超出目标范围。

公开(公告)号：EP3116996A2

公开(公告)日：2017-01-18

申请号：EP15760904.1

申请日：2015-03-16

Applicant: CoDa Therapeutics, Inc.

Inventor： EISENBUD, David ,  PHILLIPS, Anthony ,  BANNAN, Scott ,  MATSUOKA, Grove ,  DUFT, Bradford

IPC: C12N15/11 ,  C07H21/04 ,  A61K38/00

CPC classification number: C12N15/1138 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/14

Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.

Abstract translation: 提供连接蛋白调节方法和组合物用于治愈耐药性病变，包括具有多个静脉性腿部溃疡或多发性糖尿病足溃疡的受试者的损伤以及其他应答者受试者。 还提供了包含连接蛋白调节剂的试剂盒和制品，例如用于治疗耐药性病变的连接蛋白43调节剂。

公开(公告)号：EP3110455A2

公开(公告)日：2017-01-04

申请号：EP15755058.3

申请日：2015-02-25

Applicant: CoDa Therapeutics, Inc.

Inventor： PHILLIPS, Anthony ,  BANNAN, Scott ,  MATSUOKA, Grove ,  DUFT, Bradford

IPC: A61K48/00 ,  A61K38/00 ,  A61P17/02

CPC classification number: C12N15/113 ,  C12N2310/11

Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.

Abstract translation: 提供连接蛋白调节方法和组合物用于治愈耐药性病变，包括具有多个静脉性腿溃疡或多发性糖尿病足溃疡的受试者和其他响应者受试者的损伤。 还提供了包含连接蛋白调节剂（例如连接蛋白43调节剂）的试剂盒和制品，用于治愈抵抗性病变。

公开(公告)号：EP2970967A2

公开(公告)日：2016-01-20

申请号：EP14764924.8

申请日：2014-03-15

Applicant: CoDa Therapeutics, Inc.

Inventor： PHILLIPS, Anthony ,  EISENBUD, David ,  BANNAN, Scott ,  POOL, David ,  MATSUOKA, Grove ,  SUNDERLAND, Tracey ,  DUFT, Bradford

IPC: C12N15/11 ,  C12N5/00 ,  C12N5/02

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.